New hope for advanced cervical cancer: experimental drug SHR-A2102 enters phase 3 trial

NCT ID NCT07418749

Recruiting now Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing a new drug called SHR-A2102 against standard chemotherapy in 398 people with recurrent or metastatic cervical cancer that has not responded to platinum-based chemo and PD-(L)1 inhibitors. The main goal is to see if SHR-A2102 helps people live longer. Participants are randomly assigned to receive either the new drug or one of several standard chemotherapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-A2102
What this could lead to: If successful, this could offer a new treatment option for people with advanced cervical cancer that has stopped responding to standard therapies.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The drug may not work better than existing chemotherapies and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CERVICAL CANCER RECURRENT CERVICAL CANCER

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.